Pablo Legorreta, Royalty Pharma CEO (Paul Morris/Bloomberg via Getty Images)
BioCryst gets massive cash infusion to the tune of $350M, thanks to old and new investors
BioCryst is filling its coffers again — this time in $350 million cash with the help of both old and new investors.
The Durham, NC biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
